关键词: 肾综合征出血热, 灭活疫苗, 汉坦病毒, 沙鼠肾原代细胞, 灭活剂

Abstract: Objective To select the vaccine strain of hantanvirus and the cell for inculation,the immunogenicity of hantanvirus and virus titer are tested.To establish the technics of vaccine development,the vaccine,the inactived adjuvant that do not weaken the hemoglutinin of hantanvirus is selected.To develop vaccine which has low aside effect and good immunogencity preventing clinical infection of hemmorrhagic fever with renal syndrome(HFRS).Methods By immunogenicity and pretentive effect test of animal,the vaccine strain is selected from isolates of hantanvirus;In comparison with formalin,the inactive effect is observed and used as guideline;To select the cell for vaccine development,the virus titer in cell,the time that cell welt and the times of harvest are observed.Results The Z10 strain(hantaan virus) and Z37 strain(Seoul virus) of hantanvirus is selected as vaccine strain from 45 strains.Both of them have good immunogenicity and high virus titer;βpropiolactone as inactived adjuvant does not weaken the hemagglutination antigen of vaccine and have low aside effect;The primary cell of merones unguiculatus kidney tissue as virus inculation cell have high virus titer and welt well.It can also havest virus many times.Conclusion Momovalent inactive vaccine(type Ⅰ,Ⅱ)and duvalent inactive vaccine against HFRS which has been developed by Zhejiang province center for disease control and preventive have low aside effect and good immunity.All of them can can protect clinical infection of HFRS and is worthwhile to used.